2,2-bis(4-isocyanate-cyclohexyl)propane | 26189-89-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,2-bis(4-isocyanate-cyclohexyl)propane
• 英文别名: 4,4'-diisocyanato-2,2-dicyclohexylpropane；2,2-bis(4-isocyanatocyclohexyl)propane；Cyclohexane, 1,1'-(1-methylethylidene)bis[4-isocyanato-；1-isocyanato-4-[2-(4-isocyanatocyclohexyl)propan-2-yl]cyclohexane
• CAS: 26189-89-9
• 化学式: C₁₇H₂₆N₂O₂
• 分子量: 290.406
• InChiKey: LYDHLGJJJAWBDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  58.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Process for the preparation of gemcitabine chlorohydrate
  申请人：Prime European Therapeuticals S.p.A. in forma Abbreviata Euticals S.p.A.

  公开号：EP2180005A1

  公开（公告）日：2010-04-28

  Disclosed is the preparation of 2-deoxy-D-erythro-2,2-difluororibofuranose-3,5-dibenzoate: a known intermediate for the preparation of Gemcitabine, by means of a reduction process; further disclosed is the purification of Gemcitabine by chromatography and the purification of Gemcitabine hydrochloride by crystallization techniques from ternary solvent mixtures. The main advantage of the invention is providing Gemcitabine hydrochloride with purity in conformity with the Pharmacopoeia requirements, as well as a process particularly convenient from the industrial point of view.

  揭示了2-脱氧-D-赤霉糖-2,2-二氟核糖呋喃糖酸酯的制备方法： 通过还原过程制备吉西他滨的已知中间体；进一步揭示了通过色谱法纯化吉西他滨以及通过结晶技术从三元溶剂混合物中纯化吉西他滨盐酸盐的方法。该发明的主要优点是提供符合药典要求纯度的吉西他滨盐酸盐，以及从工业角度特别方便的工艺。
• PROCESS FOR THE PREPARATION OF GEMCITABINE HYDROCHLORIDE
  申请人：Varalli Alberto

  公开号：US20100105887A1

  公开（公告）日：2010-04-29

  Disclosed is the preparation of 2-deoxy-D-erythro-2,2-difluoro-ribofuranose-3,5-dibenzoate: a known intermediate for the preparation of Gemcitabine, by means of a reduction process; further disclosed is the purification of Gemcitabine by chromatography and the purification of Gemcitabine hydrochloride by crystallization techniques from ternary solvent mixtures. The main advantage of the invention is providing Gemcitabine hydrochloride with purity in conformity with the Pharmacopoeia requirements, as well as a process particularly convenient from the industrial point of view.

  揭示了2-脱氧-D-赤霉糖-2,2-二氟-3,5-二苯甲酸酯的制备方法：通过还原过程制备吉西他滨的已知中间体；进一步揭示了通过色谱法纯化吉西他滨以及通过结晶技术从三元溶剂混合物中纯化吉西他滨盐酸盐的方法。该发明的主要优点是提供符合药典要求纯度的吉西他滨盐酸盐，以及从工业角度特别方便的工艺。
• Release sustaining composition and sustained release preparation
  申请人：Hayakawa Kazuhisa

  公开号：US20050147676A1

  公开（公告）日：2005-07-07

  A release sustaining composition comprising a polyalkylene polyol derivative comprising repeating units U-1 derived from a water-soluble polyalkylene polyol and a polyisocyanate and repeating units U-2 derived from a dihydroxy compound and a polyisocyanate in a molar ratio of U-1/U-2 between 0.5/0.5 and 0.99/0.01 and optionally a water-soluble cellulose ether is combined with an active ingredient to make a sustained release preparation.

  一种持续释放组合物，包括由可溶于水的聚烯烃聚醚和聚异氰酸酯衍生的重复单元U-1以及由二羟基化合物和聚异氰酸酯衍生的重复单元U-2，在U-1/U-2的摩尔比在0.5/0.5至0.99/0.01之间，可选地与可溶于水的纤维素醚结合，用于制备持续释放制剂。
• CATALYSTS FOR THE SYNTHESIS OF OXAZOLIDINONE COMPOUNDS
  申请人：Covestro Deutschland AG

  公开号：US20170088659A1

  公开（公告）日：2017-03-30

  The present invention relates to a method for the production of oxazolidinone compounds with low colour intensity, comprising the step of reacting an isocyanate compound with an epoxide compound in the presence of a catalyst which is free of halide anions. The invention further relates to a method for the production of oligooxazolidinone and/or polyoxazolidinone compounds, comprising the step of reacting a polyisocyanate compound with a polyepoxide compound in the presence of said catalyst. The invention further relates to oligooxazolidinone and/or polyoxazolidinone compounds with low colour intensity, obtainable by a method according to the invention.

  本发明涉及一种生产低颜色强度的噁唑烷酮化合物的方法，包括在无卤化物阴离子的催化剂存在下，将异氰酸酯化合物与环氧化合物反应的步骤。该发明还涉及一种生产寡噁唑烷酮和/或聚噁唑烷酮化合物的方法，包括在所述催化剂存在下，将聚异氰酸酯化合物与聚环氧化合物反应的步骤。该发明还涉及通过本发明方法获得的低颜色强度的寡噁唑烷酮和/或聚噁唑烷酮化合物。
• CHROMENE COMPOUND, CURABLE COMPOSITION COMPRISING THE COMPOUND, AND OPTICAL ARTICLE INCLUDING A CURED BODY OF THE CURABLE COMPOSITION
  申请人：TOKUYAMA CORPORATION

  公开号：US20200190106A1

  公开（公告）日：2020-06-18

  A chromene compound having at least one indenonaphthopyran moiety which has a group forming a spiro ring together with the 13-position carbon atom and further an oligomer chain group selected from a polyalkylene oxide oligomer chain group having at least three recurring units and a polyester oligomer chain group having at least three recurring units, represented by the following formula and having reduced matrix dependence: wherein R 1 and R 2 are each a group which may have an oligomer chain group, the ring Z bonded to the 13-position carbon atom of the chromene compound is a Spiro ring group, and R 3 and R 4 are each an aryl group or heteroaryl group which may have an oligomer chain group. Preferably, the chromene compound has at least one oligomer chain group in the molecule.

  具有至少一个印苯并萘吡喃基团的色酮化合物，其中该基团与13位碳原子形成螺环，并且进一步具有从至少三个重复单元中选择的聚烷氧基寡聚物链基团和聚酯寡聚物链基团中的一个寡聚物链基团，由下式表示并具有降低的矩阵依赖性： 其中R1和R2是各自可能具有寡聚物链基团的基团，与色酮化合物的13位碳原子键合的环Z是螺环基团，而R3和R4是各自可能具有寡聚物链基团的芳基或杂环基团。最好，该色酮化合物在分子中至少具有一个寡聚物链基团。